



Contents lists available at ScienceDirect

Free Radical Biology and Medicine

journal homepage: www.elsevier.com/locate/freeradbiomed

EPR spectroscopic evidence of iron-catalysed free radical formation in chronic mountain sickness: Dietary causes and vascular consequences

Damian M. Bailey^{a,*}, Marcel Culcasi^b, Teresa Filipponi^a, Julien V. Brugniaux^{a,c}, Benjamin S. Stacey^a, Christopher J. Marley^a, Rodrigo Soria^d, Stefano F. Rimoldi^d, David Cerny^d, Emrush Rexhaj^d, Lorenza Pratali^e, Carlos Salinas Salmòn^f, Carla Murillo Jáuregui^f, Mercedes Villena^f, Francisco Villafuerte^g, Antal Rockenbauer^h, Sylvia Pietri^b, Urs Scherrer^{d,i}, Claudio Sartori^j

^a Neurovascular Research Laboratory, Faculty of Life Sciences and Education, University of South Wales, Wales, UK

^b Aix Marseille Univ, CNRS, ICR, UMR, 7273, Marseille, France

^c HP2 Laboratory, INSERM U1300, Grenoble Alpes University, Grenoble, France

^d Department of Cardiology and Biomedical Research, University Hospital, Bern, Switzerland

^e Institute of Clinical Physiology, Pisa, Italy

^f Instituto Boliviano de Biología de Altura, La Paz, Bolivia

^g Laboratorio de Fisiología Comparada, Departamento de Ciencias Biológicas y Fisiológicas, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru

^h Institute of Materials and Environmental Chemistry, Research Center for Natural Sciences, 1117, Budapest, Hungary

ⁱ Facultad de Ciencias, Departamento de Biología, Universidad de Tarapacá, Arica, Chile

^j Department of Internal Medicine, University Hospital, UNIL-Lausanne, Switzerland

ARTICLE INFO

Keywords:

Chronic mountain sickness
Free radicals
Oxidative-nitrosative stress
Systemic vascular function
Oxidative catalysis

ABSTRACT

Chronic mountain sickness (CMS) is a high-altitude (HA) maladaptation syndrome characterised by elevated systemic oxidative-nitrosative stress (OXNOS) due to a free radical-mediated reduction in vascular nitric oxide (NO) bioavailability. To better define underlying mechanisms and vascular consequences, this study compared healthy male lowlanders (80 m, n = 10) against age/sex-matched highlanders born and bred in La Paz, Bolivia (3600 m) with (CMS+, n = 10) and without (CMS-, n = 10) CMS. Cephalic venous blood was assayed using electron paramagnetic resonance spectroscopy and reductive ozone-based chemiluminescence. Nutritional intake was assessed via dietary recall. Systemic vascular function and structure were assessed via flow-mediated dilatation, aortic pulse wave velocity and carotid intima-media thickness using duplex ultrasound and applanation tonometry. Basal systemic OXNOS was permanently elevated in highlanders (P = <0.001 vs. lowlanders) and further exaggerated in CMS+, reflected by increased hydroxyl radical spin adduct formation (P = <0.001 vs. CMS-) subsequent to liberation of free 'catalytic' iron consistent with a Fenton and/or nucleophilic addition mechanism(s). This was accompanied by elevated global protein carbonylation (P = 0.046 vs. CMS-) and corresponding reduction in plasma nitrite (P = <0.001 vs. lowlanders). Dietary intake of vitamins C and E, carotene, magnesium and retinol were lower in highlanders and especially deficient in CMS+ due to reduced consumption of fruit and vegetables (P = <0.001 to 0.028 vs. lowlanders/CMS-). Systemic vascular function and structure were also impaired in highlanders (P = <0.001 to 0.040 vs. lowlanders) with more marked dysfunction observed in CMS+ (P = 0.035 to 0.043 vs. CMS-) in direct proportion to systemic OXNOS (r = -0.692 to 0.595, P = <0.001 to 0.045). Collectively, these findings suggest that lifelong exposure to iron-catalysed systemic OXNOS, compounded by a dietary deficiency of antioxidant micronutrients, likely contributes to the systemic vascular complications and increased morbidity/mortality in CMS+.

Trial registry: [ClinicalTrials.gov](https://clinicaltrials.gov); No: NCT01182792; URL: www.clinicaltrials.gov.

* Corresponding author. Royal Society Wolfson Research Fellow, Director of the Neurovascular Research Laboratory, Alfred Russel Wallace Building, Faculty of Life Sciences and Education, University of South Wales, CF37 4AT, UK.

E-mail address: damian.bailey@southwales.ac.uk (D.M. Bailey).

<https://doi.org/10.1016/j.freeradbiomed.2022.03.028>

Received 21 February 2022; Received in revised form 24 March 2022; Accepted 29 March 2022

Available online 6 April 2022

0891-5849/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Chronic mountain sickness (CMS) is a high-altitude (HA) maladaptive syndrome that affects between 5 and 10% of the world's estimated 140 million highlanders who permanently reside >2500 m above sea-level [1]. It is characterised by excessive erythrocytosis (EE) and severe hypoxemia, frequently associated with moderate to severe pulmonary hypertension, that in advanced cases may evolve to cor pulmonale, congestive heart failure and stroke [2]. Currently, there are no effective long-term treatments given its complex pathogenesis.

It is well recognised that CMS associates with pulmonary vascular dysfunction [2], with emerging evidence indicating that the systemic circulation may be equally compromised, further compounding disease risk and premature mortality. In support, more marked impairments in flow-mediated dilation (FMD) and elevations in vascular stiffness and carotid intima-media thickness (cIMT) have been observed in comparatively more hypoxemic CMS patients (CMS+) compared to healthy well-adapted highlander (CMS-) and lowlander (sea-level) controls [3–6].

While preliminary evidence supports a contributory role for an exaggerated and sustained elevation in basal systemic oxidative-nitrosative stress (OXNOS) subsequent to enhanced free radical-mediated scavenging of vascular nitric oxide (NO) bioavailability [3, 7], the contributing species, underlying mechanisms and functional significance remain obscure. Cellular hypoxia has consistently been shown to promote mitochondrial superoxide ($O_2^{\cdot-}$) formation primarily from complex III in vitro [8], due to a Na^+ -mediated reduction in mitochondrial inner membrane fluidity resulting in the entrapment and accumulation of ubiquinone at the Qo site [9]. Subsequent formation of hydrogen peroxide (H_2O_2) can diffuse rapidly into the cytoplasm, facilitated by a reduction in mitochondrial matrix and intermembrane space peroxidase activities [10] to initiate extracellular 'blood-borne' lipid peroxidation, that in the presence of 'free' ferrous (Fe^{2+}) iron (see below) can give rise to secondary lipid-derived alkoxy (LO^{\cdot}) and alkyl (LC^{\cdot}) radicals [11]. Intravascular $O_2^{\cdot-}$ can also be generated from extra-mitochondrial sources including nicotinamide adenine dinucleotide phosphate- and xanthine oxidases, cytochrome P-450 enzymes, lipoxygenases, phagocytes and hydrogen ion formation subsequent to hypoxia-induced metabolic acidosis [12–14]. These radical species are all thermodynamically capable of initiating additional chain reactions ($LO^{\cdot}/LC^{\cdot} + L-H \rightarrow L^{\cdot}$) [15] and reacting directly with intravascular NO at diffusion-controlled rates ($k = \sim 10^9$ M/s) to yield peroxynitrite ($O_2^{\cdot-}/LO^{\cdot}/LC^{\cdot} + NO \rightarrow ONOO^-$) [16] that in turn can mediate lipid peroxidation/protein tyrosine nitrosylation and uncouple endothelial NO synthase [13].

However, to what extent $O_2^{\cdot-}$ formation proceeds directly in vivo including the potential for reductive formation of Fe^{2+} (Eq. (1)) capable of catalysing Fenton (Eq. (2)) and Haber-Weiss (Eq. (3))-induced generation of hydroxyl radicals (HO^{\cdot}) has not previously been investigated. Overall, these biological pathways predominantly reflect a transition metal catalysed reaction stemming from Fridovich's original $O_2^{\cdot-}$ theory of O_2 toxicity, given that the Haber-Weiss reaction (Eq. (3)) has a negligible rate constant [17].



Furthermore, to what extent dietary deficiency of antioxidant micronutrients due to inadequate consumption of fruit and vegetables (F + V) further compounds systemic OXNOS is equally unknown, despite preliminary evidence for lower circulating concentrations of ascorbate and α/β -carotene in CMS+ [3].

To address these limitations, the present study combined electron

paramagnetic resonance (EPR) spectroscopy with ozone-based chemiluminescence (OBC) for the direct detection and molecular characterisation of OXNOS biomarkers, to test the following hypotheses. First, Me- β -cyclodextrin (Me β CD)-assisted spin trapping with the novel stereoselective phosphorylated nitron, 2-methyl-2-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphinan-2-yl)-3,4-dihydro-2H-pyrrole 1-oxide (Me₂Cy-DEPMPO), would demonstrate more marked elevations in systemic $O_2^{\cdot-}$ and HO^{\cdot} formation in CMS+ relative to healthy lowlander and CMS- controls specifically related to increased catalytic ('free') iron bioavailability. Second, this would be related to inadequate intake of antioxidant micronutrients as a consequence of lower F + V consumption. Third, exaggerated OXNOS would be associated with more marked impairments in systemic vascular function and structure extending prior observations [3,7] given its more informed mechanistic basis.

2. Methods

2.1. Ethics

The experimental protocol was approved by the Institutional Review Boards for Human Investigation at the University of San Andres, La Paz, Bolivia (CNB #52/04), Universidad Peruana Cayetano Heredia, Lima, Péru (#101686), University of Lausanne, Lausanne, Switzerland (#89/06, #94/10), and University of South Wales, Pontypridd, UK (#4/07), prior to registration in a clinical trials database (clinicaltrials.gov; Identifier: NCT01182792). All procedures adhered to the guidelines set forth in the Declaration of Helsinki and participants provided written informed consent following explanation of the purposes of clinical experimentation and risks involved.

2.2. Design

We conducted a cross-sectional, population-based, observational study in accordance with the STROBE statement [18]. The Neurovascular Research Laboratory in the UK (~80 m) and Instituto Boliviano de Biología de Altura in La Paz, Bolivia (~3600 m) were the primary sites of investigation. Select aspects of the cardiopulmonary data have previously been published as part of a wider investigation focused exclusively on the mechanisms underlying cerebrovascular dysfunction in CMS+ [7]. Thus, although the present study adopted an identical experimental design, it constitutes an entirely separate question with additional experimental measures of free radicals, catalytic iron, dietary intake and systemic vascular function and structure. Fig. 1 provides a schematic summary of the experimental design.

2.3. Participants

For all participants, inclusion criteria specified that they were born and had lived permanently at their resident altitude and were sedentary, defined as no formal recreational activity outside of everyday living [19]. Exclusion criteria included those with significant developmental delay or learning difficulties, diagnosis of any central neurological disease such as aneurysm, stroke, transient ischemic attack, epilepsy, multiple sclerosis and psychiatric disorders including any history of traumatic brain injury and hypertension. None of the participants were taking nutritional supplements including over-the-counter antioxidant or anti-inflammatory medications. We specifically chose to focus on males given their higher prevalence of CMS notwithstanding our inability to control for differences in circulating estrogen known to impact redox-regulation of systemic vascular function in females. Prior to inclusion, all participants were subject to an extensive clinical examination that consisted of a thorough medical history, chest auscultation and 12-lead ECG. Participants were subsequently familiarised with the equipment and all experimental procedures.

2.3.1. Highlanders

We recruited 10 male patients with primary CMS (CMS+) and 10 healthy age- and education-matched controls without CMS (CMS-) native to La Paz, Bolivia (Table 1). Symptoms of CMS were scored and clinical diagnosis confirmed by an excessive erythrocytosis including hemoglobin (Hb) > 20 g/dL in the presence of normal pulmonary function and no history of working in the mining industry [1]. All participants identified themselves as Aymaras and were from similar socio-economic backgrounds having been born and bred in La Paz (Cerro de Pasco for secondary study) with Spanish spoken as their first language.

2.3.2. Lowlanders

We recruited 10 age and education matched healthy Caucasian males in the UK (Table 1) who were all born and bred close to sea-level with no prior history of ascending above 1500 m.

2.4. Socioeconomic status (SES)

In addition to educational attainment (completed Secondary School/University) for the purposes of group matching, we also assessed occupational prestige using established methods that employed the 1989 modification of scores taken from the original 1980 US Census Occupational Category [20]. In brief, published scores (highest reflecting most prestigious occupation) were assigned to individual occupational titles classified under the following (nine) general categories: managerial and administrative, professional specialty, technical, sales, administrative support, service, farming/forestry/fishing, precision production/craft/repair, and laborer.

2.5. Cardiopulmonary assessments

A lead II electrocardiogram (Dual BioAmp; ADInstruments Ltd, Oxford, UK) was used to measure heart rate (HR). Finger photoplethysmography (Finometer PRO, Finapres Medical Systems, Amsterdam, The Netherlands) was used to measure beat-by-beat arterial blood pressure for calculation of mean arterial pressure (MAP), stroke volume (SV) and cardiac output (\dot{Q}) using the Modelflow algorithm [21] that incorporates participant sex, age, stature and mass (BeatScope 1.0 software; TNO; TPD Biomedical Instrumentation, Amsterdam). End-tidal partial pressures of oxygen and carbon dioxide (PET_{O₂/CO₂}) were determined from a leak-free mask and analysed via capnography (ML 206, ADInstruments). Pulse oximetry (Nonin 9550 Onyx II, Nonin Medical, Inc., Plymouth, MI, USA) was employed to determine arterial

oxyhemoglobin saturation (SaO₂) on the third digit of the right hand. Beat-by-beat data were continuously recorded at 1 kHz using an analog-to-digital converter (Powerlab/16SP ML795; ADInstruments, Colorado Springs, CO, USA) stored on a personal computer for off-line analysis (LabChart version 7.2.2, ADInstruments).

2.6. Metabolic assessments

Participants were asked to refrain from physical activity, caffeine and alcohol and maintain their normal dietary behaviors before and during formal experimentation. They were 12 h overnight fasted when they attended the laboratory at 8 a.m. We obtained blood samples without stasis following 20 min of seated rest to control for the confounds associated with plasma volume shifts.

2.6.1. Chemicals

All chemicals including dimethylsulfoxide (DMSO), Me β CD (CAS 128446-36-6), diethylenetriaminepentaacetic acid (DTPA), desferrioxamine mesylate (DFX), ferric chloride (FeCl₃), ferrous sulfate (FeSO₄), H₂O₂ and the spin trap *N*-tert-butyl- α -phenylnitron (PBN) were of the highest available purity from Sigma-Aldrich. The spin trap Me₂Cy-DEPMPO, a cyclic analogue of 5-diethoxyphosphoryl-5-methyl-1-pyrroline 1-oxide (DEPMPO; see Fig. 1 inset), was synthesised according to Ref. [22].

2.6.2. Blood sampling

Blood was obtained from an indwelling cannula located in a cephalic vein into Vacutainers® (Becton, Dickinson and Company, Oxford, UK). Centrifugation was performed at 600 g (4 °C) for 10 min to yield hemolysis-free supernatant [11]. Plasma samples were decanted directly into cryogenic vials (Nalgene® Labware, Thermo Fisher Scientific Inc, Waltham, MA, USA) and immediately snap-frozen in liquid nitrogen (N₂) and shipped/stored under N₂ gas (Cryopak, Taylor-Wharton, Theodore, AL, USA) prior to analysis in the UK. Samples were left to defrost at 37 °C in the dark for 5 min prior to batch analysis.

2.6.3. Free radicals

X-band EPR spectra were recorded at room temperature using a Bruker (Karlsruhe, Germany) EMX spectrometer, except for studies with Me₂CyDEPMPO where a Bruker ESP 300 spectrometer was used. Throughout, 100 kHz modulation frequency, 10 or 20 mW microwave power (MP) and a standard TM₁₁₀ cavity were used.

2.6.3.1. Preliminary *in vitro* EPR controls.

In order to assist the




Fig. 1. Experimental design. NO, nitric oxide; O₂⁻ superoxide anion; HO•, hydroxyl radical; CMS-/CMS+, highlanders without/with chronic mountain sickness (CMS). Red text highlights new measurements reported by the present study that compliment our previously published findings [3,7]. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Table 1
Demographics.

| Group: | Lowlanders | Highlanders | | P values | | |
|--------------------------------------|----------------------|------------------|------------------|------------------------|-----------------------|-------------------|
| Subgroup: | Controls (n = 10) | CMS- (n = 10) | CMS+ (n = 10) | CMS- vs. Controls | CMS + vs. Controls | CMS + vs. CMS- |
| Clinical | | | | | | |
| Age (y) | 57 ± 5 | 55 ± 8 | 56 ± 9 | 0.116 (between groups) | | |
| Hb (g/dL) | 14.0 ± 0.9 | 17.0 ± 1.0 | 20.3 ± 2.2 | <0.001 | <0.001 | <0.001 |
| Hct (%) | 44 ± 3 | 52 ± 4 | 62 ± 7 | 0.003 | <0.001 | <0.001 |
| SaO ₂ (%) | 97 ± 0 | 90 ± 6 | 88 ± 4 | 0.004 | <0.001 | 0.443 |
| caO ₂ (mg/dL) | 18.9 ± 1.2 | 21.3 ± 1.6 | 24.7 ± 3.0 | 0.044 | <0.001 | 0.004 |
| CMS score (points) | 0 ± 0 | 1 ± 2 | 6 ± 4 | 0.677 | <0.001 | <0.001 |
| Anthropometrics | | | | | | |
| Mass (kg) | 75.2 ± 9.3 | 71.8 ± 7.0 | 79.1 ± 11.9 | 0.256 (between groups) | | |
| Stature (m) | 1.75 ± 0.07 | 1.63 ± 0.03 | 1.61 ± 0.05 | <0.001 | <0.001 | 1.000 |
| BMI (kg/m ²) | 25 ± 3 | 27 ± 3 | 29 ± 4 | 0.349 | 0.022 | 0.629 |
| Socioeconomic status | | | | | | |
| Secondary educated (n/%) | 6/60 | 6/60 | 8/80 | 0.549 (between groups) | | |
| University educated (n/%) | 4/40 | 4/40 | 2/20 | 0.549 (between groups) | | |
| Occupational prestige (points) | 50 ± 15 | 53 ± 17 | 41 ± 10 | 0.156 (between groups) | | |
| Cardiopulmonary function | | | | | | |
| PET _{O₂} (mmHg) | 106 ± 4 | 55 ± 3 | 53 ± 4 | <0.001 | <0.001 | 0.959 |
| PET _{CO₂} (mmHg) | 41 ± 3 | 33 ± 5 | 34 ± 3 | <0.001 | 0.001 | 1.000 |
| SBP (mmHg) | 131 ± 10 | 119 ± 20 | 135 ± 19 | 0.096 (between groups) | | |
| DBP (mmHg) | 78 ± 6 | 61 ± 8 | 69 ± 9 | <0.001 | 0.066 | 0.108 |
| MAP (mmHg) | 96 ± 6 | 80 ± 11 | 91 ± 12 | 0.006 | 0.880 | 0.084 |
| HR (b/min) | 50 ± 5 | 72 ± 13 | 63 ± 7 | <0.001 | 0.013 | 0.060 |
| SV (mL) | 58 ± 10 | 97 ± 20 | 117 ± 24 | <0.001 | <0.001 | 0.074 |
| Q̇ (L/min) | 5.50 ± 0.97 | 6.87 ± 0.81 | 7.28 ± 1.33 | 0.022 | 0.002 | 1.000 |
| TPR (mmHg/L/min) | 17.73 ± 2.52 | 11.79 ± 1.68 | 12.77 ± 2.40 | <0.001 | <0.001 | 1.000 |

Values are mean ± SD; CMS-/CMS+, highlanders without/with chronic mountain sickness (CMS); BMI, body mass index; Hb, hemoglobin; Hct, hematocrit; SaO₂, arterial oxyhemoglobin saturation; caO₂, arterial oxygen content; PET_{O₂}, end-tidal partial pressure of oxygen; PET_{CO₂}, end-tidal partial pressure of carbon dioxide; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; SV, stroke volume; Q̇, cardiac output; TPR, total peripheral resistance.

assignments of Me₂CyDEPMPO adducts detected ex vivo in the blood of participants (see Results section), in vitro tests were performed in the presence of an excess of MeβCD. This cyclodextrin (Fig. S1, inset; Supplementary data) was included in the spin-trapping milieu on the basis of the reported formation of cyclodextrin-guest inclusion complexes with DEPMPO spin adducts that yield increased stability toward bioreductive EPR silencing mechanisms in buffers [23] and cells [24]. In addition, these preliminary experiments, using a Fenton driven HO• generator, determined to what extent MeβCD interferes quantitatively with (i) formation of the Me₂CyDEPMPO/HO• spin adduct (Me₂CyDEPMPO-OH) in phosphate buffer solution (PBS, pH 7.4) and (ii) formation of Me₂CyDEPMPO/methyl radical spin adduct (Me₂CyDEPMPO-Me) when the generator used in (i) was run in the presence of the competitive inhibitor DMSO, supplemented in the buffer. A typical Me₂CyDEPMPO-OH control generating system in PBS (20 mM) for experiments (i) contained Me₂CyDEPMPO (30 mM), H₂O₂ (1 mM), with final addition of FeSO₄ (1 mM) to catalyse HO• formation. In these systems MeβCD (50 mM) was added to (i) 30 s before or after addition of iron salt. In Me₂CyDEPMPO-Me generating experiments, MeβCD (50 mM) was added before iron to the milieu described in (i), that also contained DMSO (10% v/v). Samples were placed in 50 μL glass capillary tubes (Hirschmann Laborgeräte, Germany) and sealed with Critoseal®. Single-scan EPR spectra were sequentially recorded 1–18 min following addition of iron salt with the following parameters: MP, 10 mW; magnetic field resolution (R), 2048 points; modulation amplitude (MA), 0.521 G; receiver gain (RG), 2 × 10⁵; time constant (TC), 81.92 ms; sweep rate (SR), 1.55 G/s for a sweep width (SW) of 130 G.

2.6.3.2. Ex-vivo EPR studies in blood. Three experiments were performed for the molecular detection and characterisation of free radicals in blood.

[i] **MeβCD-assisted spin-trapping on Me₂CyDEPMPO:** Heparinised whole blood samples (1 mL) were obtained from all participants and placed into 2 mL cryovial tubes pre-filled with a mixture of (final concentration) 0.2 mM DTPA, 80 mM MeβCD, 40 mM PBS and 0.5 mL of aqueous Me₂CyDEPMPO (0.1 M), and immediately frozen in liquid N₂. EPR acquisition in glass capillaries was initiated 1 min after complete thawing with the same parameters as for preliminary tests above, except that 2 cumulative scans were averaged due to low signal-to-noise ratio. In both in vitro and ex vivo experiments using Me₂CyDEPMPO, relative spin adduct concentrations were derived from the simulated spectra [25] and the unequivocal assignment of *trans*-/*cis*-Me₂CyDEPMPO-OH and *trans*-Me₂CyDEPMPO-Me adducts (see Fig. 2A, with R = Me) was based on the close similarity (<5%) of their calculated EPR hyperfine couplings (hfcs) with those reported earlier using the same free radical generators in buffer [22].

PBN spin trapping and catalytic iron experiments were conducted in a random subsample of 5 CMS + patients to provide additional ‘proof-of-concept’ insight into the mechanisms underlying Me₂CyDEPMPO-OH adduct(s) formation (see Limitations).

[ii] **Spin-trapping using PBN:** Whole blood (4.5 mL) was added to a 6 mL glass vacutainer (SST) primed with 1.5 mL of cold freshly prepared PBN dissolved in physiological saline (50 mM final concentration). The vacutainer was gently mixed then placed in the dark to clot for 10 min. Following centrifugation, 1.5 mL of the serum-adduct was removed, flash-frozen and stored in liquid N₂ prior to batch analysis. During the analysis, samples were thawed on ice and 1 mL of the serum-adduct was added to a borosilicate glass tube containing 1 mL of spectroscopic grade toluene and vortex-mixed for 10 s. The sample was centrifuged for a




Fig. 2. Cyclodextrin-assisted in vitro and ex vivo spin-trapping with $\text{Me}_2\text{CyDEPMPO}$ and protein carbonyl formation in highlanders' blood

A. Chemical structure of 2-methyl-2-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphinan-2-yl)-3,4-dihydro-2H-pyrrole 1-oxide ($\text{Me}_2\text{CyDEPMPO}$) and formation of *trans/cis* diastereoisomers in the spin trapping of HO^\bullet and alkyl radicals. Inset: Structure of DEPMPO . B. Typical EPR signals at room temperature in the blood of CMS- vs. CMS+ highlanders. Immediately after drawing, samples were supplemented with $\text{Me}_2\text{CyDEPMPO}$ (0.1 M) and $\text{Me}\beta\text{CD}$ (80 mM) before being quickly frozen. Best fits yielded mixtures of *trans/cis* diastereoisomeric OH and alkyl adducts with hfcs (in G): CMS-: *trans*-OH: $a_N = 13.87$, $a_P = 48.76$, and $a_H^\beta = 12.18$ G; *cis*-OH: $a_N = 14.23$, $a_P = 50.20$ and $a_H^\beta = 13.53$ G; alkyl: $a_N = 15.97$, $a_P = 47.92$ and $a_H^\beta = 22.43$; CMS+: *trans*-OH: $a_N = 13.70$, $a_P = 48.53$ and $a_H^\beta = 12.45$ G; *cis*-OH: $a_N = 14.15$, $a_P = 50.35$ and $a_H^\beta = 14.57$ G; alkyl: $a_N = 14.33$, $a_P = 50.34$ and $a_H^\beta = 20.43$. Relative intensities are highlighted and the low-field lines of alkyl and OH adducts are visualised by the grey and black arrows, respectively. C. Spin adducts intensities (mean \pm SD) in CMS- (n = 10) vs. CMS+ (n = 10) highlanders, with no adducts detected in lowlander blood. D. Basal protein carbonyls (mean \pm SD) in CMS- (n = 10) vs. CMS+ (n = 10) highlanders.

further 10 min and 200 μL of the organic supernatant added to a (N_2 -flushed) precision-bore quartz EPR tube and vacuum-degassed to remove O_2 prior to EPR spectroscopy. All sample handling was performed in a darkened room to minimise photolytic degradation. Instrument settings were: MP, 20 mW; R, 4096 points; MA, 0.5 G; RG, 1.0×10^5 ; TC, 82 ms; SW, 50 G, for 10 cumulative scans.

[iii] **Catalytic iron:** Additional EPR measurements were performed on the same blood samples as in (ii). The basic principle of the assay, which relies on relative changes in the EPR signal intensity of the persistent ascorbate radical A^\bullet (yielding an EPR doublet with a_H

~ 1.76 G; Fig. 3) during air auto-oxidation of ascorbate, has been used for probing catalytic iron ex vivo [26]. Briefly, separate vials of serum (200 μL) were treated with 500 μM (final concentration) of DFX (reduces iron-catalysed oxidation) and 10 μM of $\text{FeCl}_3\text{-EDTA}$ (stimulates iron catalysed oxidation). Instrument settings were: MP, 20 mW; R, 4096 points; MA, 2.0 G; RG, 1.0×10^5 ; TC, 41 ms; SW, 10 G, for 15 cumulative scans. Spectra were filtered identically using Bruker WinEPR version 2.11 software and simulated using Bruker SimFonia or SimEPR32 (Bruker Biospin) [27]. Relative free radical concentrations were calculated by double integration of simulations using Origin 8 software




Fig. 3. EPR studies of catalytic iron and PBN spin adducts. A. Changes in A^\bullet concentration following ex vivo addition of DFX (500 μM) and Fe(III)-EDTA (10 μM) to blood obtained from CMS+ highlanders. Values are mean \pm SD (n = 5) and expressed relative to ambient ascorbate concentration. B. Formation of alkoxy radical (RO^\bullet) PBN spin adduct (PBN-OR). C. Typical PBN-OR EPR signals ($a_N = 13.59$ G and $a_H^\beta = 1.85$ G) observed in blood from a CMS+ patient. Inset: Typical baseline A^\bullet EPR doublet and structure of A^\bullet showing main coupling hydrogen (in bold).

(OriginLab Corp., Northampton, MA, USA). We also chose to 'normalise' A⁻ formation for differences in ambient ascorbate concentrations. Following deproteination with 10% metaphosphoric acid, ascorbate was assayed via fluorimetry based on the condensation of dehydroascorbic acid with 1,2-phenylenediamine [28].

2.6.4. Protein carbonyls (PC)

Plasma was diluted with 4 vol of PBS 0.1X prior to analysis and 100 µL placed in 96-well microplates and left to react for 15 min at 21 °C with an aliquot (100 µL) of the NBDH assay solution (Carbofax®, Yelen Analytics, Marseille, France) [29]. Concentration of NBDH-reacted PC was determined by fluorescence (emission determined at 560 nm using an excitation wavelength at 480 nm) with reduced/oxidized bovine serum albumin employed as calibrants. The concentration of PC was calculated relative to total protein content, the latter determined using the Pierce BCA protein assay kit (Fisher Scientific, France). Intra- and inter-assay CVs were <10%.

2.6.5. NO metabolites

Plasma NO metabolites were measured via reductive ozone-based chemiluminescence (Sievers NOA 280i, Analytix Ltd, Durham, UK) [30]. Plasma (200 µL) was injected into tri-iodide reagent for the combined measurement of nitrite and S-Nitrosothiols (NO₂⁻ + RSNO). A separate sample (400 µL) was mixed with 5% acidified sulphanylamide (9:1) and left to incubate in the dark at 21 °C for 15 min to remove NO₂⁻ prior to injection into tri-iodide reagent for the direct measurement of RSNO. Plasma NO₂⁻ was subsequently calculated as (NO₂⁻ + RSNO) - RSNO. Total NO bioactivity was calculated as the cumulative concentration of all metabolites. Signal output was plotted against time using Origin 8 software and smoothed using a 150-point averaging algorithm. The Peak Analysis package was used to calculate the area under the curve and subsequently converted to a concentration using standard curves of sodium NO₂⁻. Intra- and inter-assay CVs for all metabolites were <10%.

2.6.6. Iron metabolites

Iron metabolism was assessed in a separate group of age-matched lowlanders/highlanders given ethical constraints imposed during blood volume sampling in the primary study. Serum iron and transferrin were measured using a colorimetric and immunoturbidimetric assay respectively via the C501 module on a Cobas 6000 analyzer (Roche) (32). Serum ferritin was determined using an electrochemiluminescence immunoassay using a Cobas e601 module (Roche). Assuming that 1 mol of transferrin (molecular mass 79,570 Da) has the capacity to bind two atoms of iron (atomic mass 56), transferrin saturation (TSAT) was calculated as [31]:

$$\text{TSAT}(\%) = \frac{\text{Serum iron } (\mu\text{g/dL})}{\text{Transferrin } (\text{mg/dL})} \times 70.9$$

Total iron binding capacity (TIBC) was calculated as:[31]

$$\text{TIBC} = (\mu\text{g/dL}) = \text{Transferrin } (\text{mg/dL}) \times 1.41$$

2.8. Dietary analysis

Nutritional intake was assessed using the 24 h dietary recall (24-HDR) method conducted on two separate days [32]. The 24-HDR is considered the least biased structured self-report instrument that is the most accurate for low income populations [33,34]. Participants were asked to provide detailed information about the food and beverages consumed including preparation methods, ingredients used, amount consumed, leftover, brand name of commercial products, time of the day and type of meal. Standard household measuring tools, food models,

photos and other visual aids were also employed to help judge and estimate portion size in order to improve accuracy. Dietary data were analysed using NetWISP dietary analysis software (Version 4.0, Tinuviel Software; Anglesey, UK).

2.9. Vascular assessments

All resting measurements were performed following 10 min of supine rest, breathing room air at each respective location at the prevailing barometric pressures (normoxic normocapnia for lowlanders, hypoxic hypocapnia for highlanders).

2.9.1. Systemic arterial function

Systemic conduit artery endothelial function was assessed by determining the increase of the brachial artery (BA) diameter evoked during reactive hyperemia using high-resolution ultrasound and automatic wall tracking software [35] according to International Guidelines [36]. Briefly, the BA was identified approximately 5 cm above the antecubital fossa with high-resolution duplex ultrasound (Acuson Sequoia C512, Acuson Siemens, Mountain View, CA, USA or Esaote MyLab30 Gold, Genova, Italy) and a high frequency (7–10 MHz) linear array probe. The ultrasound probe was fixed in a stereotactic clamp (AMC Vascular Imaging, Amsterdam) and flow recorded continuously throughout. After 1 min of baseline measurements, a pressure cuff placed around the forearm was inflated to 250 mmHg for 5 min. Following cuff-deflation, the hyperemia-induced changes in BA diameter and flow were continuously monitored for 3 min. B-mode ultrasound images were analysed with a validated system for automatic real-time measurement of BA diameter (FMD Studio, Computer Vision Group, Pisa, Italy) [37]. Flow-mediated dilation (FMD) was expressed as the maximal percentage change in BA diameter from baseline and allometrically scaled (adjusted FMD) to account for differences in baseline BA diameter [38]. Endothelium-independent dilation was assessed by measuring the percentage increase in BA diameter to an acute oral dose (250 µg) of glyceryl trinitrate (GTN; UCB-Pharma SA). The intra-observer CV was <5%.

2.9.2. Systemic arterial stiffness

In accordance with International Guidelines [39], large artery stiffness was assessed non-invasively via the carotid-femoral pulse wave velocity (PWV) using the Complior® device (Artech Medical, Pantin, France) [39,40]. Briefly, common carotid and femoral arterial pressure waveforms were recorded simultaneously with mechano-transducers. The mean wave transit time for 10 heart beats was calculated by the system software using the foot-to-foot method. To determine aortic PWV (aPWV), the surface distance between the recording sites was determined with a flexible tape measure. Central pulse wave analysis was performed non-invasively using the SphygmoCor® system (AtCor Medical Pty Ltd, Sydney, Australia). The radial artery pressure waveform was recorded at the wrist using applanation tonometry with a high-fidelity micromanometer (SPT-301, Millar Instruments, Houston, TX, USA) and the central (ascending aortic) pressure waveform derived using a validated transfer function [41]. Aix was calculated as the difference between the 1st and 2nd peaks of the central arterial waveform, expressed as a percentage of the pulse pressure (PP) and normalised to 75 b/min heart rate (Aix-75) [42]. The intra-observer CV for all metrics was <5%.

2.9.3. Systemic arterial structure

Duplex ultrasound scanning of the right and left common carotid arteries (CCA), carotid bifurcations and the origin of the internal carotid arteries was performed in conjunction with simultaneous ECG acquisition in participants placed supine with slight hyperextension of the neck at 45°. The right and left carotid arteries were imaged in the anterolateral, posterolateral and mediolateral planes, 1–2 cm proximal to the carotid bulb to identify the optimal angle of incidence [43,44].

Radiofrequency signals with a 21 μm resolution (RF QIMT, Esaote, Genova, Italy) were employed to measure cIMT. After scanning the vessel, each radiofrequency line was automatically analysed forward and backward in real time by the echo-device at a site free of any discrete plaque. The mean of 3 measures from the right and 3 from the left carotid artery was documented. The intra-observer CV was <5%.

2.10. Statistical analysis

2.10.1. Power calculation

Prospective power calculations were performed using G* Power 3.1 software. Given the lack of pilot data in Me₂CyDEPMPO-adducts in CMS+/CMS-, we focused on baseline differences in (absolute) FMD and aPWV based on our prior research. Assuming comparable differences and corresponding effect sizes (η = 0.51 for FMD and 0.55 for aPWV), we required a total sample size ranging from 12 to 15 participants (4–5 per group) to achieve a power of 0.80 at P < 0.05. We chose to further inflate to a total sample size of 30 (10 per group) to accommodate potential data loss (prospective power of >0.95).

2.10.2. Inferential statistics

Data were analysed using the Statistics Package for Social Scientists (IBM SPSS Statistics V 28.0). Shapiro-Wilk W tests (P > 0.05) confirmed that all data sets were normally distributed. Demographic (Table 1), dietary (Table 2), and metabolic (Table 3) data were analysed using one-way analyses of variance (ANOVA) and *post-hoc* Bonferonni-adjusted independent samples *t*-tests assuming a main effect was observed. Relationships between variables were assessed using Pearson Product Moment Correlations. Significance was established at P < 0.05 for all two-tailed tests (with individual P values for all comparisons shown) and data expressed as mean ± standard deviation (SD).

3. Results

3.1. Demographics

By design, groups were of a similar age and educational attainment, whereas highlanders, in particular CMS+, were more hypoxemic, hypocapnic and erythrocytotic (Table 1). Despite comparable body

Table 2
Dietary intake.

| Group: | Lowlanders | Highlanders | | P values | | | Guidelines | |
|------------------------------------|-------------------|---------------|---------------|------------------------|--------------------|----------------|------------|-----------|
| Subgroup: | Controls (n = 10) | CMS- (n = 10) | CMS+ (n = 10) | CMS- vs. Controls | CMS + vs. Controls | CMS + vs. CMS- | UK | Bolivia |
| Energy & macronutrients | | | | | | | | |
| Energy (Kcal) | 2300 ± 287 | 2292 ± 499 | 2299 ± 584 | 0.999 (between groups) | | | 2581 Kcal | 2648 Kcal |
| Protein (%) | 17 ± 3 | 15 ± 4 | 18 ± 4 | 0.355 (between groups) | | | 15% | 10–15% |
| Carbohydrate (%) | 49 ± 10 | 55 ± 12 | 50 ± 10 | 0.361 (between groups) | | | 50% | 55–65% |
| Total fat (%) | 34 ± 9 | 30 ± 10 | 31 ± 14 | 0.741 (between groups) | | | ≤35% | 25–30% |
| Saturated fat (%) | 11 ± 5 | 11 ± 4 | 10 ± 4 | 0.728 (between groups) | | | ≤10% | ≤10% |
| Free sugars (%) | 9 ± 4 | 8 ± 4 | 9 ± 5 | 0.905 (between groups) | | | ≤5% | <10% |
| Fibre (%) | 20 ± 5 | 21 ± 8 | 16 ± 8 | 0.282 (between groups) | | | 30 g | 20–30 g |
| Fruit & vegetables | | | | | | | | |
| Fruits (g) | 424 ± 166 | 240 ± 147 | 199 ± 125 | 0.028 | 0.006 | 1.000 | 160–400 g | 160–400 g |
| Vegetables (g) | 389 ± 123 | 299 ± 111 | 160 ± 93 | 0.237 | <0.001 | 0.025 | 160–400 g | 160–480 g |
| Vitamins | | | | | | | | |
| Vitamin C (mg) | 87 ± 15 | 66 ± 35 | 36 ± 16 | 0.175 | <0.001 | 0.026 | 40 mg | 50 mg |
| Vitamin E (mg) | 9.01 ± 1.71 | 4.64 ± 1.46 | 3.22 ± 1.57 | <0.001 | <0.001 | 0.169 | >4 mg** | ND |
| Carotene* (μg) | 4.10 ± 1.27 | 2.45 ± 1.30 | 2.15 ± 1.19 | 0.020 | 0.005 | 1.000 | >9 mg** | ND |
| Minerals | | | | | | | | |
| Magnesium (mg) | 386 ± 83 | 279 ± 68 | 261 ± 107 | 0.033 | 0.011 | 1.000 | 300 mg | ND |
| Selenium (μg) | 57 ± 20 | 51 ± 16 | 56 ± 20 | 0.742 (between groups) | | | 75 μg | ND |
| Retinol (μg) | 421 ± 299 | 191 ± 102 | 216 ± 126 | 0.042 | 0.081 | 1.000 | 700 μg | 600 μg |
| Iron (mg) | 14.26 ± 2.89 | 13.27 ± 3.30 | 12.52 ± 3.54 | 0.498 (between groups) | | | 8.70 mg | 10–28 mg |
| Copper (mg) | 1.24 ± 0.57 | 1.41 ± 0.32 | 1.17 ± 0.32 | 0.444 (between groups) | | | 1.20 mg | ND |

Values are mean ± SD. Guidelines based on British [54] and Bolivian [55] reference values. *Sum of α/β-carotene and cryptoxanthins. **No Reference Nutrient Intake set, recommendation expressed as Safe Intake [54]. ND, not determined.

Table 3
Systemic arterial function and structure.

| Group: | Lowlanders | Highlanders | | P values | | |
|------------------------|-------------------|---------------|---------------|-------------------------|--------------------|----------------|
| Subgroup: | Controls (n = 10) | CMS- (n = 10) | CMS+ (n = 10) | CMS- vs. Controls | CMS + vs. Controls | CMS + vs. CMS- |
| Function | | | | | | |
| Baseline diameter (mm) | 4.69 ± 0.70 | 4.20 ± 0.33 | 4.64 ± 0.69 | 0.162 (between groups) | | |
| Absolute FMD (%) | 7.7 ± 2.5 | 5.4 ± 1.2 | 3.8 ± 1.1 | 0.017 | <0.001 | 0.142 |
| Adjusted FMD (%) | 7.9 ± 1.3 | 4.9 ± 1.6 | 4.0 ± 1.3 | <0.001 (between groups) | | |
| GTN, Δ diameter (%) | NA | 11.9 ± 2.7 | 8.8 ± 2.0 | NA | NA | 0.010 |
| Stiffness | | | | | | |
| Central SBP (mm Hg) | 101 ± 9 | 126 ± 10 | 124 ± 10 | <0.001 | <0.001 | 1.000 |
| Central DBP (mm Hg) | 90 ± 17 | 76 ± 6 | 76 ± 8 | 0.040 | 0.040 | 1.000 |
| aPWV (m/s) | 7.13 ± 0.73 | 8.87 ± 1.24 | 10.26 ± 1.58 | 0.011 | <0.001 | 0.043 |
| AIx-75 (%) | 17 ± 6 | 21 ± 7 | 23 ± 9 | 0.145 (between groups) | | |
| Structure | | | | | | |
| cIMT (mm) | NA | 0.64 ± 0.12 | 0.74 ± 0.12 | NA | NA | 0.035 |

Values are mean ± SD. FMD, flow-mediated dilation; GTN, glyceryl tri-nitrate; SBP, systolic blood pressure; DBP, diastolic blood pressure; aPWV, aortic pulse wave velocity; AIx-75, augmentation index normalised to heart rate of 75 b/min; Δ, change relative to baseline; cIMT, carotid intima-media thickness; NA, not assessed.

mass, CMS+ were generally shorter with a corresponding higher BMI and waist-to-hip ratio (Table 1). Resting HR, SV and Q̇ were generally elevated and PET_{O2}, PET_{CO2}, DBP and TPR were lower in the highlanders (Table 1). No between differences were observed in any of the SES metrics including occupational prestige scores (Table 1).

3.2. Metabolic assessments

3.2.1. In vitro studies (quality control)

3.2.1.1. Me β CD does not affect Me₂CyDEPMPO spin adduct formation in vitro. Trapping of Fenton-derived HO• on Me₂CyDEPMPO (30 mM) in plain PBS yielded a primary symmetrical 14-lined EPR spectrum with calculated hfcs consistent with a mixture of *trans*-Me₂CyDEPMPO-OH (*trans*-OH; a_N = 13.94 G, a_P = 48.89 G, a_H^β = 12.40 G) and *cis*-Me₂CyDEPMPO-OH (*cis*-OH; a_N = 13.93 G, a_P = 50.59 G, a_H^β = 14.08 G) diastereoisomers (Fig. 1B) [17]. A small contaminant Me₂CyDEPMPO/alkyl radical adduct (Fig. 1B; a_N = 14.46 G, a_P = 50.79 G, a_H^β = 20.86 G; ~10% of the total signal), likely a decomposition nitroxide, was also detected. A typical signal recorded 2 min after HO• formation was triggered is illustrated in Fig. S1A (Supplementary data). Strikingly, inclusion of excess Me β CD (50 mM) in the above [Fenton + nitron] system yielded mixtures of *trans*-OH, *cis*-OH and alkyl spin adducts with EPR spectra retaining similar shapes and hfcs within experimental accuracy (Figs. S1B and C and Table S1; Supplementary data). This implies a general lack of coordination between Me β CD and these spin adducts that would typically yield distorted EPR signals characteristic of the superimposition of free and complexed radicals, as reported for the DEPMPO/superoxide (-OOH) adduct [19]. However, a near two-fold decrease in the total EPR signal was observed when Me β CD was present before vs. after Fenton-induced Me₂CyDEPMPO-OH formation, reflecting competitive ‘side attack’ of HO• on the Me β CD backbone forming non-spin-trapped radicals (Fig. S1; Supplementary data). Accordingly, pre-inclusion of Me β CD in a [Fenton + DMSO] system also resulted in a loss of intensity for the expected *trans*-Me₂CyDEPMPO-Me signal [17], with formation of a strong unassigned alkyl adduct that may have originated from the Me β CD structure (Fig. S1D; Supplementary data).

3.2.1.2. Stability of Me₂CyDEPMPO adducts and *trans*-OH/*cis*-OH ratios.

All spin adduct concentrations decreased progressively with time (up to 15 min after iron added), with no clear influence of Me β CD (Fig. 2SA, B; Supplementary data). Signal acquisitions started 1 min after thawing of the sample given that we anticipated weak EPR signals in blood [Me₂CyDEPMPO + Me β CD]. Here, *trans*/*cis* ratios recorded after 2 min of continuous Fenton-mediated HO• formation were in general agreement with the published value of 1.4 (AU) observed in the same conditions for a stopped Fenton reagent [22], except when CD was added before the Fenton reaction, where the ratios were considerably higher (Fig. S2C; Supplementary data).

3.2.2. Ex vivo studies (clinical experimentation)

3.2.2.1. Me₂CyDEPMPO spin-trapping in the presence of Me β CD. Unlike lowlanders (no adducts detected), highlander blood was paramagnetic and consistently exhibited either a single component consistent with a Me₂CyDEPMPO-alkyl adduct (i.e., having a_H ~20 G; all CMS-, all CMS+) or combination of *cis*/*trans*-Me₂CyDEPMPO-OH and -alkyl adducts (one CMS-, all CMS+). In combination with the in vitro controls (above), all EPR spectra in blood were satisfactorily simulated assuming that no penetration of spin adducts in the inner cavity of CD occurred. Representative EPR spectra obtained from a (single) lowlander, CMS- participant and CMS + patient with simulated composite adducts and relative intensities are illustrated in Fig. 2B. The group signal intensities of total and composite Me₂CyDEPMPO-OH adducts (no difference in -alkyl adducts) were consistently higher in CMS+ (Fig. 2C) representing 8 ± 25% (CMS-) vs. 45 ± 18% (CMS+, P = 0.001) for Me₂CyDEPMPO-OH and 92 ± 25% (CMS-) vs. 55 ± 18% (CMS+, P = 0.001) Me₂CyDEPMPO-alkyl adducts respectively, of the total signal intensities recorded. The *trans*:*cis* ratios for CMS- was 1.427 AU (n = 1) and 1.741 ± 0.266 (1.151–2.125) AU for CMS+.

3.2.2.2. PC. Baseline PC were higher in CMS + compared to CMS- (Fig. 2D).

3.2.2.3. Catalytic iron. Compared to control (untreated) samples, DFX decreased A⁻ by 30 ± 12% (P = 0.029) whereas Fe(III)-EDTA increased A⁻ by 125 ± 17% (P = 0.002). Differences persisted following correction for ambient ascorbate (Fig. 3A, B).

3.2.2.4. PBN spin-trapping. We observed EPR sextets from toluene-extracted blood samples with a primary signal that was consistent with an alkoxyl adduct (PBN-OR: a_N = 13.59 G; a_H^β = 1.85 G, Fig. 3C, D).

3.2.2.5. NO metabolites. Total bioactive NO was consistently suppressed in highlanders due to lower NO₂⁻ whereas no differences were observed in RSNO (Fig. 4A). Both NO₂⁻ and RSNO were comparable between CMS+ and CMS- (Fig. 4A).

3.2.2.6. Iron metabolism (sub-study). No between group differences were observed in total iron, ferritin, transferrin, TSAT or TIBC (Table S2; Supplementary data).

3.3. Dietary intake

Caloric and macronutrient (protein, carbohydrate, fat and fiber) intake were comparable across groups and generally consistent with current recommendations (Table 2). In contrast, F + V consumption was markedly lower in highlanders resulting in a reduced intake of vitamins C and E, carotene, magnesium and retinol compared to lowlanders (Table 2). The lower vegetable and vitamin C intake was more pronounced in CMS + compared to CMS- (Table 2).

3.4. Vascular assessments

3.4.1. Function

Baseline BA diameters were similar across groups (Table 3). Absolute and adjusted FMD were consistently lower in highlanders, although no differences were observed between CMS+ and CMS- (Table 3). In contrast, GTN-induced dilation was lower in CMS + compared to CMS- (Table 3), although there was a tendency for baseline BA diameter to be higher (4.69 ± 0.55 mm vs. 4.27 ± 0.32 mm, P = 0.086).

3.4.2. Stiffness

Central SBP was consistently higher and central DBP lower in highlanders, whereas no differences were observed between CMS+ and CMS- (Table 3). In contrast, aPWV was elevated in highlanders and greater in CMS + compared to CMS- (Table 3). No between group differences were observed in AIX-75 (Table 3).

3.4.3. Structure

Elevated cIMT was observed in CMS + compared to CMS- (Table 3).

3.5. Correlational analyses

3.5.1. Me₂CyDEPMPO adducts, NO₂⁻ and CMS

Inverse relationships were observed between Me₂CyDEPMPO-alkyl and NO₂⁻ (Fig. 5 A) and FMD (Fig. 5 B) in CMS+. A positive relationship was observed between (total) Me₂CyDEPMPO-OH/alkyl adducts and CMS scores (Fig. 5 C) in the highlanders (pooled CMS- and CMS+).

3.5.2. NO₂⁻ and vascular function

In all participants (pooled Lowlanders, CMS- and CMS+), a positive relationship was observed between NO₂⁻ and absolute FMD (Fig. 5 D) with inverse relationships between NO₂⁻ and aPWV (Fig. 5 E) and AIX-75 (Fig. 5 F).




Fig. 4. Nitric oxide metabolites. Values are mean \pm SD ($n = 10$ per group); NO_2^- , nitrite; RSNO, S-Nitrosothiols. Inset top right highlights typical (raw) composite signals observed in a single participant before ($\text{NO}_2^- + \text{RSNO}$) and after (RSNO, please see Methods) sulphanimide incubation.

4. Discussion

The present study has identified three important findings that extend our understanding of redox-regulated mechanisms underlying lifelong mal/adaptation to HA. First, basal systemic OXNOS was permanently elevated in highlanders and further exaggerated in CMS+. This was reflected by elevated global protein carbonylation implying increased oxidation and $\text{HO}\bullet$ formation subsequent to liberation of ‘free’ catalytic iron consistent with a Fenton and/or NA mechanism(s), coupled with lower NO_2^- . Second, this was accompanied by inadequate intake of select antioxidant micronutrients due to lower F + V consumption. Third, we confirm that systemic vascular function and structure were collectively more impaired in CMS+ in direct proportion to the systemic OXNOS response. Collectively, these findings are the first to suggest that lifelong exposure to iron-catalysed systemic OXNOS, compounded by a dietary deficiency of antioxidant micronutrients, likely contributes to the systemic vascular complications and increased morbidity/mortality in CMS+.

4.1. Systemic OXNOS and iron catalysis

We specifically employed EPR spin-trapping with $\text{Me}_2\text{CyDEPMPO}$ to optimise detection of blood-borne O_2^- and $\text{HO}\bullet$ given short half-lives and established roles in regulating vascular endothelial function either directly or through secondary formation of reactive oxygen/nitrogen species [45]. We also chose to include an excess of $\text{Me}\beta\text{CD}$ in the trapping milieu to further improve adduct stability by forming inclusion complexes that protect against ascorbate, α -tocopherol and glutathione-induced bioreduction to EPR ‘silent’ hydroxylamines [23, 24]. Importantly, control experiments confirmed that $\text{Me}\beta\text{CD}$ did not affect $\text{Me}_2\text{CyDEPMPO}$ spin adduct formation in vitro, yet despite our best efforts, we consistently failed to detect $\text{Me}_2\text{CyDEPMPO-OOH}$ adducts in participants’ blood.

In contrast, highlander blood exhibited paramagnetic spectra consistent with *cis/trans*- $\text{Me}_2\text{CyDEPMPO-OH}$ and/or -alkyl adducts with the former selectively elevated in CMS+ in direct proportion to CMS scores. The average OH-adduct concentration was comparable to that induced by maximal exercise in lowlanders following 2-hydroxypropyl- β -CD-assisted DEPMPO spin-trapping [46] at identical (final) concentrations to those employed herein, placing the magnitude of ‘basal’ oxidative stress to which the CMS + patient is chronically exposed over their lifetime into clearer perspective.

In chiral nitrones such as DEPMPO or $\text{Me}_2\text{CyDEPMPO}$ that form EPR distinguishable *cis/trans*-OH diastereoisomers upon trapping $\text{HO}\bullet$, the *trans/cis* ratio determined under controlled conditions (e.g. at a given time after direct inhibition of HO-adduct formation) can differentiate between competing mechanisms that give rise to $\text{Me}_2\text{CyDEPMPO-OH}$. These include (i) bioreduction of primary $\text{Me}_2\text{CyDEPMPO-OOH}$ by endogenous thiols or enzymes including reduced glutathione (GSH) and glutathione peroxidase (GPx), (ii) direct trapping of biologically relevant $\text{HO}\bullet$ by a metal ion-catalysed (e.g. Fe^{2+}) Fenton mechanism initiated by dismutation of primary O_2^- to H_2O_2 (Eq. (2)) and (iii) nucleophilic addition (NA) of water to the nitronyl function catalysed by metal ions such as Fe^{3+} (Forrester–Hepburn mechanism) that can be released during systemic OXNOS and subsequently reduced to Fe^{2+} by O_2^- (Eq. (1)) [22,47,48].

The *trans:cis* ratios obtained in CMS + patients were more consistent with a Fenton and/or NA mechanism (typical ratios of ~ 1.4 AU observed in vitro), since appreciably higher ratios (~ 3.0 AU) arise during GSH + GPx-induced reduction of primary OOH [22]. While this may argue against O_2^- formation, it is conceivable that OOH-adducts may have initially formed, yet were rapidly reduced to OH-adducts before entry into the $\text{Me}\beta\text{CD}$ inner cavity requisite for EPR detection. This is plausible given that the oxidative stress cascade is typically initiated by O_2^- with $\text{HO}\bullet$ formed as a secondary species.




Fig. 5. Relationships observed between free radical metabolism and systemic vascular function. Me₂CyDEPMPO, 2-methyl-2-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphinan-2-yl)-3,4-dihydro-2H-pyrrole 1-oxide; OH, hydroxyl; FMD, flow-mediated dilation; PWV, pulse wave velocity; AIx-75, augmentation index normalised to heart rate of 75 b/min; CMS-/CMS+, highlanders without/with chronic mountain sickness (CMS). Note that only significant (i.e., $P < 0.05$) correlations are included.

Detection of A[•], albeit in a random (sub) sample of CMS + patients, suggests that ‘free’ iron was bioavailable with a catalytic efficiency comparable to Fe(III)-EDTA, lending further support to the proposed Fenton and/or NA mechanisms. This was complimented by detection of PBN-adducts assigned to secondary •OR formed downstream of Fe²⁺-catalysed reductive decomposition of lipid hydroperoxides (LOOH) since equivalent hfc’s have been observed in vitro following (Fe²⁺-catalysed) auto-oxidation of cumene-OOH [3]. That the minor signal ascribed to Me₂CyDEPMPO-alkyl adducts were likely artefacts

originating from the Me β CD structure potentially explains why further elevation was not observed in CMS+. In contrast, carbonylation was selectively elevated indicating that proteins are more vulnerable to OXNOS-mediated oxidative damage to amino acid side chains and protein backbone [49].

The complimentary examination of iron metabolites indicated that free iron in CMS + did not arise as a result of iron exceeding transferrin binding capacity since TSAT, as indeed all associated metrics, were normal and comparable to healthy lowlander/CMS- participants.

Intravascular hemolysis caused by mechanical stress associated with increased intrinsic blood viscosity [6] and/or oxidative damage to the RBC membrane [50] is a plausible alternative. In support, a recent study documented an inverse relationship between free plasma haptoglobin and hematocrit in CMS+, suggesting that these patients are potentially exposed to lifelong hemolysis [51].

4.2. Dietary antioxidants

Only one study has previously estimated dietary intake in CMS+, albeit using a non-validated questionnaire limited to vitamins A, C and E. Despite indirect evidence for elevated lipid peroxidation in (Andean) CMS+, vitamin intake was comparable to healthy lowlander and CMS-controls [52]. In contrast, our validated, more comprehensive approach identified that intake of select antioxidant micronutrients including vitamins C and E, carotene, magnesium and retinol was generally lower in highlanders due to reduced F + V consumption.

Although the traditional Bolivian diet is predominantly based on foods of plant origin including potatoes and cereals, F + V have been subject to frequent price increases [53] that may have contributed to the lower consumption observed. However, why intake was further suppressed in CMS + remains unclear, especially in light of comparable SES. Indeed, vegetable and vitamin C intake were especially inadequate, falling below the minimum amount advised by UK [54] and Bolivian [55] Governments.

Our findings disagree with the latest Bolivian households' survey data [53] and first comprehensive review of dietary intake in Andean countries, indicating that vitamin C intake is generally sufficient in this population [56]. Inadequate intake may thus contribute, at least in part, to the lower systemic concentration of ascorbate (in combination with α - and β -carotene) previously documented in CMS+ [3]. This may further enhance vulnerability to OXNOS-mediated impairments in systemic vascular endothelial function and structure (see 4.3) given that ascorbate is the primary water-soluble chain-breaking antioxidant required for targeted 'repair' of O_2^- , $HO\bullet$, alkyl, peroxy, $\bullet OR$ and tocopheroxyl radicals during chain propagation, the latter synergising regeneration of α -tocopherol, the primary fat-soluble chain-breaking antioxidant [57].

Equally, lower dietary intake of nitrate, primarily sourced through green, leafy vegetables with bioactivity (likely) further reduced due to overcooking [58] when added to traditional Bolivian 'sopas' (soups), may have also contributed to the lower plasma NO_2^- observed (4.2.). Clinically, inadequate F + V compounds OXNOS and increases corresponding risk of cardiovascular disease (CVD) and stroke [59], the primary causes of mortality in CMS + patients who exhibit >3.6 fold higher CVD risk relative to healthy CMS- [60]. It has recently been identified that ≈ 5 daily servings daily of F + V confers the lowest risk of total and cause-specific mortality (albeit in lowlanders), with 2 (daily) servings for fruit and 3 for vegetables identified as the minimum required for risk reduction [59].

Clearly, the dietary behavior of CMS + patients in the present study places them at higher CVD risk yet provides an opportunity for therapeutic intervention (pharmacological and/or dietary) in a bid to bolster endogenous antioxidant defences. Our findings provide a mechanistic basis justifying implementation of a prospective randomised trial to assess the impact of dietary manipulation on CMS + given that OXNOS and corresponding hemodynamic risk factors may be at least, partially reversible. This may take the form of a randomised, controlled parallel-group community trial with CMS + patients randomly assigned to either an interventional (encouraged to consume 5 daily servings of F + V consistent with aforementioned guidelines [59], also incorporating transtheoretically-determined readiness for change combined with educational activities and problematising-dialogic pedagogy [61]) or control (maintenance of habitual dietary intake) group. We recommend a trial duration of 6 months given that this approach has been shown to augment circulating water and lipid-phase antioxidants (α -carotene, β -carotene, lutein, β -cryptoxanthin and ascorbic acid) and improve

corresponding vascular function (reduction in systolic/diastolic blood pressure) [62].

4.3. Systemic vascular function and structure

In addition to direct scavenging of endothelial NO via diffusion-limited reactions with O_2^- , $RO\bullet$ and $RC\bullet$ [16], hemolysis-induced extravasation of cell-free Hb into plasma can further compound elimination via additional Fenton, NO dioxygenation [$Hb-Fe^{2+}(O_2) + NO \rightarrow Hb-Fe^{3+}OONO\bullet / NO_3^-$] and iron nitrosylation of deoxy-Hb [$Hb-Fe^{2+} + NO \rightarrow Hb(NO)$] reactions [63]. These outcompete reaction with intra-erythrocytic Hb by ~ 1000 -fold [64], reducing rates of S-nitrosothiol formation and/or deoxyHb-mediated reduction of NO_2^- to NO, stable (i.e. RBC-encapsulated) metabolites that conserve/transfer bioactivity within the hypoxic microcirculation. Indeed, hemolysis-induced NO scavenging and corresponding impairments in vascular endothelial function are common to (other) diseases characterised by increased RBC mass, including polycythemia vera and Chuvash polycythemia [65].

In the present study, plasma NO_2^- was generally lower in highlanders' blood and consistently associated with reduced systemic vascular endothelial function (FMD), elevated arterial stiffness (aPWV/AIx-75) and morphological impairment (elevated cIMT) confirming our prior observations [3,5]. However, that plasma NO_2^- was not further reduced in CMS + despite more pronounced impairments in systemic vascular function and structure, suggests that vasculopathic complications cannot solely be ascribed to disordered NO metabolism (notwithstanding interpretive challenges associated with a small sample size, see 4.4. Experimental limitations). In support and contrary to prior observations [3,5], GTN-induced dilation was also selectively attenuated in CMS + albeit complicated by a tendency towards an elevated baseline diameter (arguably constraining further vasodilation), tentatively implying additional impairments in smooth muscle function and/or structure previously ascribed to direct vasculotoxic/constrictive effects of hypoxia-induced O_2^- formation [66].

Intriguingly, aPWV widely considered the gold standard metric of aortic stiffness and independent predictor of coronary heart disease and stroke [67], provided the most robust differences and associations distinguishing vascular impairment in CMS+. While we cannot discount (aforementioned) statistical idiosyncrasies associated with a small sample size combined with differences in biomarker sensitivity/specificity, our findings tentatively suggest that elevated OXNOS may have selectively targeted (impaired) aortic stiffness over vascular endothelial function. Although speculative, this may be due to the fact that aortic stiffness is largely governed by structural degeneration of the scaffolding proteins, collagen and elastin, that are especially (if not perhaps more) vulnerable to mitochondrial ROS [68]. Fig. 6 provides an overall schematic summarising the proposed molecular pathways underlying systemic OXINOS and corresponding link(s) to vasculopathic complications of CMS (including novel contributions in the present study), extending our previously published findings [3,7].

4.4. Experimental limitations

Several limitations warrant careful consideration to provide a more balanced perspective to the present findings. All findings were based exclusively on cross-sectional comparisons and correlational analyses in the absence of mediation analysis, warranting future interventional approaches to better define a causal role for OXNOS as mediators of vascular dysfunction and/or CMS disease process (see 4.5 Conclusions).

We also acknowledge the interpretive limitations associated with a relatively small sample size and associated loss of statistical power; including caveats associated with Type II and M errors [69], that for select variables, in particular FMD, AIX-75, NO_2^- and vitamin E, limited our ability to detect post-hoc differences between CMS+ and CMS-. In




Fig. 6. Summary schematic of the molecular pathways and link(s) to systemic vascular function/structural impairments in chronic mountain sickness.

I. Proposed stimuli underlying systemic activation of the oxidative nitrosative stress (OXNOS) pathway. II. Proposed OXNOS pathway highlighting free radical sources, mechanisms of formation and corresponding targets. Intravascular (mitochondrial/extramitochondrial) superoxide (O_2^-) and corresponding reductive formation of Fe^{2+} (ferrous iron) can catalyse Fenton/nucleophilic addition/hemolysis-induced generation of hydroxyl ($\text{HO}\cdot$) and other secondary lipid-derived alkoxy/alkyl radicals ($\text{LO}\cdot/\text{LC}\cdot$). These species are thermodynamically capable of causing oxidative damage to proteins including red blood cells and reacting directly with nitric oxide (NO) reducing bioavailability for smooth-muscle cells. Lifelong exposure to iron-catalysed systemic OXNOS, compounded by a dietary deficiency of antioxidant micronutrients, likely contributes to the vasculopathic complications and increased morbidity/mortality observed in CMS. Note those variables highlighted in red (filled boxes or text) indicate additional advances reported by the present study that compliment our previously published findings, providing additional mechanistic insight into the systemic OXNOS pathway [3,7]. PaO_2 , arterial partial pressure of oxygen; SaO_2 , arterial oxyhemoglobin saturation; F + V, fruit and vegetables; O_2^- superoxide anion; Fe^{3+} , ferric iron; H_2O_2 , hydrogen peroxide; $\text{Me}_2\text{CyDEPMPPO-OH}$, 2-methyl-2-(5,5-dimethyl-1-2-oxo-1,3,2-dioxaphosphinan-2-yl)-3,4-dihydro-2H-pyrrole 1-oxide-hydroxyl adduct; LOOH, lipid hydroperoxides; $\text{LOO}\cdot$, lipid peroxy radical; ONOO^- , peroxynitrite; $\text{Hb-Fe}^{2+}(\text{O}_2)$, ferrous oxyhemoglobin; Hb-Fe^{3+} , methemoglobin; NO_3^- , nitrate; $\text{Hb}(\text{NO})$, iron-nitrosylhemoglobin; GTN-FMD, glyceryl trinitrate-stimulated FMD (endothelium-independent), flow-mediated dilatation (endothelium-dependent); aPWV, aortic pulse wave velocity; cIMT, carotid intima-media thickness. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

terms of (absolute %) FMD values, we (retrospectively) observed an effect size of 1.067 and corresponding power of 0.998 ($\alpha = 0.05$), having adhered strictly to established guidelines that have been shown to reduce variability [70], indicating that our study was well powered to detect a treatment effect. However, our conservative approach (Bonferroni adjustments to control for false positives), combined with recent evidence documenting CVs of 16.6% and 14.2% and intra-class correlation coefficients of 0.528 and 0.714 for intra- and inter-session brachial FMD test-retests respectively [71] suggests that this technique is at best, only ‘moderately’ reliable, that warrants consideration during

future research.

We also recognise the need to exercise caution when attempting to unequivocally assign spin-adducts to specific free radical species/mechanisms; while these can be better approached in vitro using ‘stopped generators’, this was not possible ex vivo given that continuous free radical formation persists over the course of blood sampling, notwithstanding the potential for artefactual $\text{O}_2^-/\text{HO}\cdot$ generation during the course of incubation and sample processing. Indeed, this is a universal challenge when attempting to detect ‘any’ reactive metabolite ex vivo in the human circulation (i.e. not just free radicals) that are

formed clearly downstream of the primary reaction pathway that we assume reflects dynamic events in vivo. Recently, we pretreated PBN trapped blood with ethylgallimidate in an attempt to inhibit (neutrophil) NADPH oxidase activation as originally recommended [11], although initial findings indicated this had little to no measurable effect in terms of PBN-OR formation (DM Bailey, unpublished observations). Follow-up quality control approaches are warranted given the reactivity of free radicals and complexity of blood as a biological matrix. Future studies aimed at elucidating the targets of the generated O_2^- and $HO\bullet$ are also warranted, including ‘proteomics’ to explore the thiol redox proteome [72] and ‘immuno-spin trapping’ that combines the specificity of spin trapping with improved sensitivity of immunological techniques with nitron adducts that can be detected by mass spectrometry, NMR or immunochemistry using *anti*-DMPO nitron antibodies [73,74].

Due to logistics constraints, lowlander controls were recruited from the UK and not Bolivia. Expected differences in socio-cultural influences (e.g., access to healthcare, social/family structure) likely complicated our ability to accurately distinguish whether observed differences were due to HA residence or CMS per se. Likewise, future researchers need to consider investigating females, especially those who are postmenopausal, given that this is a risk factor for CMS [75]. Furthermore, catalytic iron detection and general assessment of iron metabolism were confined to either a select (sub) sample of CMS + patients or entirely separate group respectively, as ‘follow-ups’ upon successful detection of $Me_2CyDEPMPO-OH$ adducts. Complimentary assays of intravascular hemolysis specifically cell-free Hb, hemopexin and haptoglobin are also encouraged in future studies to complement the present findings.

Finally, while select aspects of elevated OXNOS biomarkers and systemic vascular dysfunction have previously been reported in CMS+ [3,7], the new data generated by the present study (Fig. 6) further extends our mechanistic understanding of the systemic OXNOS pathway.

4.5. Conclusions

In conclusion, the present study suggests that elevated systemic OXNOS and associated vasculopathic complications in CMS + may be the consequence of iron-induced oxidative catalysis that may have a Fenton/NA/hemolytic basis. Future studies need to further differentiate these mechanisms and consider related pharmacological/dietary approaches that selectively target the OXNOS pathway including iron chelation (e.g. desferroxamine) to constrain iron-mediated oxidative catalysis. Equally, prospective randomised trials and/or public health interventions aimed at encouraging more F + V consumption will help address dietary antioxidant deficiency, reduce vulnerability to OXNOS and improve clinical outcome.

Funding

This work was supported by a Royal Society Wolfson Research Fellowship (#WM170007) and grants from the Higher Education Funding Council for Wales (DMB), Swiss National Science Foundation, Cloëtta Foundation, Eagle Foundation, Leenaards Foundation and Placide Nicod Foundation (US and CS).

Author contributions

DMB, US and CS obtained funding, conceived and designed the research. DMB, MC, TF, JVB, BS, CJM, RS, SFR, DC, ER, LP, CSS, CMJ, MV, FV, AR, SP, US and CS contributed to data collection and/or analysis. DMB, MC, TF, AR, SP, US and CS interpreted the results of the experiments. DMB drafted the first draft manuscript and revisions thereof with input from MC, US and CS. DMB, MC, TF, JVB, BS, CJM, RS, SFR, DC, ER, LP, CSS, CMJ, MV, FV, AR, SP, US and CS edited and revised the manuscript(s) and approved the final version submitted for publication.

Declaration of competing interest

The authors declare that they have no competing interests.

Acknowledgements

We thank Mrs Catherine Romero and staff of the Instituto Boliviano de Biología de Altura (La Paz, Bolivia) for technical support. ADInstruments provided exceptional technical input/support during the period of data logging. We also thank Professor Martina Muckenthaler (University of Heidelberg, Heidelberg, Germany) for specialist input relating to iron metabolism.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.freeradbiomed.2022.03.028>.

References

- [1] F. Leon-Velarde, M. Maggiorini, J.T. Reeves, A. Aldashev, I. Asmus, L. Bernardi, R. L. Ge, P. Hackett, T. Kobayashi, L.G. Moore, D. Penalzoza, J.P. Richalet, R. Roach, T. Wu, E. Vargas, G. Zubieta-Castillo, G. Zubieta-Calleja, Consensus statement on chronic and subacute high altitude diseases, *High Alt. Med. Biol.* 6 (2) (2005) 147–157.
- [2] D. Penalzoza, J. Arias-Stella, The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness, *Circulation* 115 (9) (2007) 1132–1146.
- [3] D.M. Bailey, S.F. Rimoldi, E. Rexhaj, L. Pratali, C. Salinas Salmon, M. Villena, J. McEneny, I.S. Young, P. Nicod, Y. Allemann, U. Scherrer, C. Sartori, Oxidative-nitrosative stress and systemic vascular function in highlanders with and without exaggerated hypoxemia, *Chest* 143 (2) (2013) 444–451.
- [4] E. Rexhaj, S.F. Rimoldi, L. Pratali, R. Brenner, D. Andries, R. Soria, C. Salinas, M. Villena, C. Romero, Y. Allemann, A. Lovis, R. Heinzer, C. Sartori, U. Scherrer, Sleep-disordered breathing and vascular function in patients with chronic mountain sickness and healthy high-altitude dwellers, *Chest* 149 (4) (2016) 991–998.
- [5] S.F. Rimoldi, E. Rexhaj, L. Pratali, D.M. Bailey, D. Hutter, F. Fata, C. Salinas Salmon, M. Villena, P. Nicod, Y. Allemann, U. Scherrer, C. Sartori, Systemic vascular dysfunction in patients with chronic mountain sickness, *Chest* 141 (1) (2012) 139–146.
- [6] J.C. Tremblay, R.L. Hoiland, C.A. Howe, G.B. Coombs, G.A. Vizardo-Galindo, R. J. Figueroa-Mujica, D. Bermudez, T.D. Gibbons, B.S. Stacey, D.M. Bailey, M. M. Tymko, D.B. MacLeod, C. Gasho, F.C. Villafuerte, K.E. Pyke, P.N. Ainslie, Global REACH 2018: high blood viscosity and hemoglobin concentration contribute to reduced flow-mediated dilation in high-altitude excessive erythrocytosis, *Hypertension* 73 (6) (2019) 1327–1335.
- [7] D.M. Bailey, J.V. Brugniaux, T. Filipponi, C.J. Marley, B. Stacey, R. Soria, S. F. Rimoldi, D. Cerny, E. Rexhaj, L. Pratali, C.S. Salmon, C. Murillo Jauregui, M. Villena, J.D. Smirl, S. Ogoh, S. Pietri, U. Scherrer, C. Sartori, Exaggerated systemic oxidative-inflammatory-nitrosative stress in chronic mountain sickness is associated with cognitive decline and depression, *J. Physiol.* 597 (2) (2019) 611–629.
- [8] K.A. Smith, G.B. Waypa, P.T. Schumacker, Redox signaling during hypoxia in mammalian cells, *Redox Biol.* 13 (2017) 228–234.
- [9] P. Hernansanz-Agustin, C. Choya-Foces, S. Carregal-Romero, E. Ramos, T. Oliva, T. Villa-Pina, L. Moreno, A. Izquierdo-Alvarez, J.D. Cabrera-Garcia, A. Cortes, A. V. Lechuga-Vieco, P. Jadiya, E. Navarro, E. Parada, A. Palomino-Antolin, D. Tello, R. Acin-Perez, J.C. Rodriguez-Aguilera, P. Navas, A. Cogolludo, I. Lopez-Montero, A. Martinez-Del-Pozo, J. Egea, M.G. Lopez, J.W. Elrod, J. Ruiz-Cabello, A. Bogdanova, J.A. Enriquez, A. Martinez-Ruiz, Na(+) controls hypoxic signalling by the mitochondrial respiratory chain, *Nature* 586 (7828) (2020) 287–291.
- [10] M.P. Murphy, How mitochondria produce reactive oxygen species, *Biochem. J.* 417 (1) (2009) 1–13.
- [11] D.M. Bailey, S. Taudorf, R.M.G. Berg, C. Lundby, J. McEneny, I.S. Young, K. A. Evans, P.E. James, A. Shore, D.A. Hullin, J.M. McCord, B.K. Pedersen, K. Moller, Increased cerebral output of free radicals during hypoxia: implications for acute mountain sickness? *Am. J. Physiol.* 297 (5) (2009) R1283–R1292.
- [12] D.M. Bailey, P. Rasmussen, K.A. Evans, A.M. Bohm, M. Zaar, H.B. Nielsen, P. Brassard, N.B. Nordsborg, P.H. Homann, P.B. Raven, J. McEneny, I.S. Young, J. M. McCord, N.H. Secher, Hypoxia compounds exercise-induced free radical formation in humans; partitioning contributions from the cerebral and femoral circulation, *Free Radical Biol. Med.* 124 (2018) 104–113.
- [13] T. Munzel, A. Daiber, V. Ullrich, A. Mulsch, Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase, *Arterioscler. Thromb. Vasc. Biol.* 25 (8) (2005) 1551–1557.
- [14] P. Hernansanz-Agustin, A. Izquierdo-Alvarez, F.J. Sanchez-Gomez, E. Ramos, T. Villa-Pina, S. Lamas, A. Bogdanova, A. Martinez-Ruiz, Acute hypoxia produces a superoxide burst in cells, *Free Rad. Biol. Med.* 71 (2014) 146–156.

- [15] G.R. Buettner, The pecking order of free radicals and antioxidants: lipid peroxidation, α -tocopherol, and ascorbate, *Arch. Biochem. Biophys.* 300 (2) (1993) 535–543.
- [16] T. Nauser, W.H. Koppenol, The rate constant of the reaction of superoxide with nitrogen monoxide: approaching the diffusion limit, *J. Phys. Chem.* 106 (2002) 4084–4086.
- [17] I. Fridovich, The biology of oxygen radicals, *Science* 201 (4359) (1978) 875–880.
- [18] E. von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Gøtzsche, J. P. Vandenbroucke, S. Initiative, The strengthening of reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, *Int. J. Surg.* 12 (12) (2014) 1495–1499.
- [19] D.M. Bailey, C.J. Marley, J.V. Brugniaux, D. Hodson, K.J. New, S. Ogoh, P. N. Ainslie, Elevated aerobic fitness sustained throughout the adult lifespan is associated with improved cerebral hemodynamics, *Stroke* 44 (11) (2013) 3235–3238.
- [20] K. Fujishiro, J. Xu, F. Gong, What does “occupation” represent as an indicator of socioeconomic status?: exploring occupational prestige and health, *Soc. Sci. Med.* 71 (2010) 2100–2107.
- [21] K.H. Wesseling, J.R. Jansen, J.J. Settels, J.J. Schreuder, Computation of aortic flow from pressure in humans using a nonlinear, three-element model, *J. Appl. Physiol.* 74 (5) (1993) 2566–2573.
- [22] G. Gosset, J.L. Clément, M. Culcasi, A. Rockenbauer, S. Pietri, CyDEPMPOs: a class of stable cyclic DEPMPO derivatives with improved properties as mechanistic markers of stereoselective hydroxyl radical adduct formation in biological systems, *Bioorg. Med. Chem.* 19 (7) (2011) 2218–2230.
- [23] H. Karoui, A. Rockenbauer, S. Pietri, P. Tordo, Spin trapping of superoxide in the presence of beta-cyclodextrins, *Chem. Commun.* (24) (2002) 3030–3031.
- [24] K. Abbas, M. Hardy, F. Poulhes, H. Karoui, P. Tordo, O. Ouari, F. Peyrot, Detection of superoxide production in stimulated and unstimulated living cells using new cyclic nitron spin traps, *Free Rad. Biol. Med.* 71 (2014) 281–290.
- [25] A. Rockenbauer, L. Korecz, Automatic computer simulation of ESR spectra, *Appl. Magn. Reson.* 10 (1996) 29–43.
- [26] G. Buettner, W. Chamulitrat, The catalytic activity of iron in synovial fluid as monitored by the ascorbate free radical, *Free Rad. Biol. Med.* 8 (1) (1990) 55–56.
- [27] A. Adamski, T. Spalek, A. Sojka, Application of EPR spectroscopy for elucidation of vanadium speciation in VOx/ZrO₂ catalysts subject to redox treatment, *Res. Chem. Intermed.* 29 (2003) 793–804.
- [28] J.P. Vuilleumier, E. Keck, Fluorimetric assay of vitamin C in biological materials using a centrifugal analyser with fluorescence attachment, *J. Micronutr. Anal.* 5 (1993) 25–34.
- [29] P. Stocker, M. Cassien, N. Vidal, S. Thétiot-Laurent, S. Pietri, A fluorescent homogeneous assay for myeloperoxidase measurement in biological samples. A positive correlation between myeloperoxidase-generated HOCl level and oxidative status in STZ-diabetic rats, *Talanta* 170 (2017) 119–127.
- [30] D.M. Bailey, P. Rasmussen, M. Overgaard, K.A. Evans, A.M. Bohm, T. Seifert, P. Brassard, M. Zaar, H.B. Nielsen, P.B. Raven, N.H. Secher, Nitrite and S-Nitrosohemoglobin exchange across the human cerebral and femoral circulation: relationship to basal and exercise blood flow responses to hypoxia, *Circulation* 135 (2) (2017) 166–176.
- [31] I. Kasvosve, J. Delanghe, Total iron binding capacity and transferrin concentration in the assessment of iron status, *Clin. Chem. Lab. Med.* 40 (10) (2002) 1014–1018.
- [32] R.S. Gibson, *Principles of Nutritional Assessment*, Oxford University Press, New York, USA, 2005.
- [33] R.S. Gibson, U.R. Charrondiere, W. Bell, Measurement errors in dietary assessment using self-reported 24-hour recalls in low-income countries and strategies for their prevention, *Adv. Nutr.* 8 (2017) 980–991.
- [34] F.E. Thompson, A.F. Subar, Dietary assessment methodology, in: A.M. Coulston, C. J. Boushey, M.G. Ferruzzi (Eds.), *Nutrition in the Prevention and Treatment of Disease*, Academic Press, London, UK, 2017, pp. 5–48.
- [35] P.Y. Jayet, S.F. Rimoldi, T. Stuber, C.S. Salmon, D. Hutter, E. Rexhaj, S. Thalmann, M. Schwab, P. Turini, C. Sartori-Cucchia, P. Nicod, M. Villena, Y. Allemann, U. Scherrer, C. Sartori, Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia, *Circulation* 122(5) 488–494.
- [36] J. Deanfield, A. Donald, C. Ferri, C. Giannattasio, J. Halcox, S. Halligan, A. Lerman, G. Mancina, J.J. Oliver, A.C. Pessina, D. Rizzoni, G.P. Rossi, A. Salvetti, E. L. Schiffrin, S. Taddei, D.J. Webb, Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the working group on endothelin and endothelial factors of the European society of hypertension, *J. Hypertens.* 23 (1) (2005) 7–17.
- [37] V. Gemignani, F. Fata, L. Ghiadoni, E. Poggianti, M. Demi, A system for real-time measurement of the brachial artery diameter in B-mode ultrasound images, *IEEE Trans. Med. Imag.* 26 (3) (2007) 393–404.
- [38] G. Atkinson, A.M. Batterham, The percentage flow-mediated dilation index: a large-sample investigation of its appropriateness, potential for bias and causal nexus in vascular medicine, *Vasc. Med.* 18 (6) (2013) 354–365.
- [39] S. Laurent, J. Cockcroft, L. Van Bortel, P. Boutouyrie, C. Giannattasio, D. Hayoz, B. Pannier, C. Vlachopoulos, I. Wilkinson, H. Struijker-Boudier, Expert consensus document on arterial stiffness: methodological issues and clinical applications, *Eur. Heart J.* 27 (21) (2006) 2588–2605.
- [40] R. Asmar, A. Benetos, J. Topouchian, P. Laurent, B. Pannier, A.M. Brisac, R. Target, B.I. Levy, Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies, *Hypertension* 26 (3) (1995) 485–490.
- [41] M. O'Rourke, Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension, *Hypertension* (15) (1990) 339–347.
- [42] I.B. Wilkinson, H. MacCallum, L. Flint, J.R. Cockcroft, D.E. Newby, D.J. Webb, The influence of heart rate on augmentation index and central arterial pressure in humans, *J. Physiol.* 525 Pt 1 (2000) 263–270.
- [43] J.H. Stein, C.E. Korcarz, R.T. Hurst, E. Lonn, C.B. Kendall, E.R. Mohler, S.S. Najjar, C.M. Rembold, W.S. Post, Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine, *J. Am. Soc. Echocardiogr.* 21 (2) (2008) 93–111.
- [44] P.J. Touboul, M.G. Hennerici, S. Meairs, H. Adams, P. Amarenco, N. Bornstein, L. Csiba, M. Desvarieux, S. Ebrahim, M. Fatar, R. Hernandez Hernandez, M. Jaff, S. Kownator, P. Prati, T. Rundek, M. Sitzer, U. Schminke, J.C. Tardif, A. Taylor, E. Vicaud, K.S. Woo, F. Zannad, M. Zureik, Mannheim carotid intima-media thickness consensus (2004–2006), in: *An Update on Behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004*, and Brussels, Belgium, 2006 vol. 23, *Cerebrovascular Disorders*, 2007, pp. 75–80, 1.
- [45] J.N. Copley, M.L. Fiorello, D.M. Bailey, 13 reasons why the brain is susceptible to oxidative stress, *Redox Biol.* 15 (2018) 490–503.
- [46] D.M. Bailey, K.A. Evans, J. McEneny, I.S. Young, D.A. Hullin, P.E. James, S. Ogoh, P.N. Ainslie, C. Lucchesi, A. Rockenbauer, M. Culcasi, S. Pietri, Exercise-induced oxidative stress is associated with impaired dynamic cerebral autoregulation and blood-brain barrier leakage, *Exp. Physiol.* 96 (11) (2011) 1196–1207.
- [47] C. Fréjaville, H. Karoui, B. Tuccio, F. Le Moigne, M. Culcasi, S. Pietri, R. Lauricella, P. Tordo, 5-(Diethoxyphosphoryl)-5-methyl-1-pyrroline N-oxide: a new efficient phosphorylated nitron for the in vitro and in vivo spin trapping of oxygen-centered radicals, *J. Med. Chem.* 38 (2) (1995) 258–265.
- [48] M. Culcasi, A. Rockenbauer, A. Mercier, J.L. Clément, S. Pietri, The line asymmetry of electron spin resonance spectra as a tool to determine the cis:trans ratio for spin-trapping adducts of chiral pyrrolines N-oxides: the mechanism of formation of hydroxyl radical adducts of EMPO, DEPMPO, and DIPPMPPO in the ischemic-reperfused rat liver, *Free Radic. Biol. Med.* 40 (9) (2006) 1524–1538.
- [49] E.R. Stadtman, R.L. Levine, Free radical-mediated oxidation of free amino acids and amino acid residues in proteins, *Amino Acids* 25 (3–4) (2003) 207–218.
- [50] O.G. Luneva, S.V. Sidorenko, O.O. Ponomarchuk, A.M. Tverskoy, A.A. Cherkashin, O.V. Rodnenkov, N.V. Alekseeva, L.I. Deev, G.V. Maksimov, R. Grygorczyk, S. N. Orlov, Deoxygenation affects composition of membrane-bound proteins in human erythrocytes, *Cell. Physiol. Biochem.* 39 (1) (2016) 81–88.
- [51] J.L. Macarlupu, G. Vizcardo-Galindo, R. Figueroa-Mujica, N. Voituron, J. P. Richalet, F.C. Villafuerte, Sub-maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness, *Exp. Physiol.* (2021).
- [52] J.A. Jefferson, J. Simoni, E. Escudero, M.E. Hurtado, E.R. Swenson, D.E. Wesson, G. F. Schreiner, R.B. Schoene, R.J. Johnson, A. Hurtado, Increased oxidative stress following acute and chronic high altitude exposure, *High Alt. Med. Biol.* 5 (1) (2004) 61–69.
- [53] F.J. Pérez-Cueto, A. Naska, J. Monterrey, M. Almanza-Lopez, A. Trichopoulos, P. Kolsteren, Monitoring food and nutrient availability in a nationally representative sample of Bolivian households, *Br. J. Nutr.* 95 (3) (2006) 555–567.
- [54] D.o. Health, *Dietary Reference Values for Food and Nutrients for the United Kingdom*. Report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy, 1991. London, UK.
- [55] M.d.s.d. Bolivia, *Ministerio de Salud, Bases técnicas de las guías alimentarias para la población Boliviana*, 2014, pp. 1–100. La Paz, Bolivia.
- [56] P.R. Berti, C. Fallu, Y. Cruz Agudo, A systematic review of the nutritional adequacy of the diet in the Central Andes, *Rev. Panam. Salud Pública* 36 (5) (2014) 314–323.
- [57] M. Sharma, G. Buettner, Interaction of vitamin C and vitamin E during free radical stress in plasma: an ESR study, *Free Radical Biol. Med.* 14 (6) (1993) 649–653.
- [58] A. Ahluwalia, M. Gladwin, G.D. Coleman, N. Hord, G. Howard, D.B. Kim-Shapiro, M. Lajous, F.J. Larsen, D.J. Lefer, L.A. McClure, B.T. Nolan, R. Pluta, A. Schechter, C.Y. Wang, M.H. Ward, J.L. Harman, Dietary nitrate and the epidemiology of cardiovascular disease: report from a national heart, lung, and blood institute workshop, *J. Am. Heart Assoc.* 5 (7) (2016).
- [59] D.D. Wang, Y. Li, S.N. Bhupathiraju, B.A. Rosner, Q. Sun, E.L. Giovannucci, E. B. Rimm, J.E. Manson, W.C. Willett, M.J. Stampfer, F.B. Hu, Fruit and vegetable intake and mortality: results from 2 prospective cohort studies of US men and women and a meta-analysis of 26 cohort studies, *Circulation* 143 (17) (2021) 1642–1654.
- [60] N. Corante, C. Anza-Ramirez, R. Figueroa-Mujica, J.L. Macarlupu, G. Vizcardo-Galindo, G. Bilo, G. Parati, J.L. Gamboa, F. Leon-Velarde, F.C. Villafuerte, Excessive erythrocytosis and cardiovascular risk in andean highlanders, *High Alt. Med. Biol.* 19 (3) (2018) 221–231.
- [61] M.C. Menezes, R.D. Mendonca, N.L. Ferreira, L.M.F. Guimaraes, A.C.S. Lopes, Promoting fruit and vegetable consumption: methodological protocol of a randomized controlled community trial, *Contemp. Clin. Trials Commun.* 10 (2018) 131–136.
- [62] J.H. John, S. Ziebland, P. Yudkin, L.S. Roe, H.A. Neil, F. Oxford, G. Vegetable Study, Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial, *Lancet* 359 (9322) (2002) 1969–1974.
- [63] G.J. Kato, M.H. Steinberg, M.T. Gladwin, Intravascular hemolysis and the pathophysiology of sickle cell disease, *J. Clin. Invest.* 127 (3) (2017) 750–760.
- [64] C.D. Reiter, X. Wang, J.E. Tanus-Santos, N. Hogg, R.O. Cannon 3rd, A.N. Schechter, M.T. Gladwin, Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease, *Nat. Med.* 8 (12) (2002) 1383–1389.

- [65] M.T. Gladwin, R.P. Patel, The role of red blood cells and hemoglobin-nitric oxide interactions on blood flow, *Am. J. Respir. Cell Mol. Biol.* 38 (2) (2008) 125–126.
- [66] N.C. Lewis, D.M. Bailey, G.R. Dumanoir, L. Messinger, S.J. Lucas, J.D. Cotter, J. Donnelly, J. McEneny, I.S. Young, M. Stenbridge, K.R. Burgess, A.S. Basnet, P. N. Ainslie, Conduit artery structure and function in lowlanders and native highlanders: relationships with oxidative stress and role of sympathoexcitation, *J. Physiol.* 592 (5) (2014) 1009–1024.
- [67] G.F. Mitchell, S.J. Hwang, R.S. Vasan, M.G. Larson, M.J. Pencina, N.M. Hamburg, J.A. Vita, D. Levy, E.J. Benjamin, Arterial stiffness and cardiovascular events: the framingham heart study, *Circulation* 121 (4) (2010) 505–511.
- [68] R.H. Zhou, A.E. Vendrov, I. Tchivilev, X.L. Niu, K.C. Molnar, M. Rojas, J.D. Carter, H. Tong, G.A. Stouffer, N.R. Madamanchi, M.S. Runge, Mitochondrial oxidative stress in aortic stiffening with age: the role of smooth muscle cell function, *Arterioscler. Thromb. Vasc. Biol.* 32 (3) (2012) 745–755.
- [69] A. Gelman, J. Carlin, Beyond power calculations: assessing type S (sign) and type M (magnitude) errors, *Perspect. Psychol. Sci.* 9 (6) (2014) 641–651.
- [70] A. Greyling, A.C. van Mil, P.L. Zock, D.J. Green, L. Ghiadoni, D.H. Thijssen, T.I.W. G.o.F.M. Dilation, Adherence to guidelines strongly improves reproducibility of brachial artery flow-mediated dilation, *Atherosclerosis* 248 (2016) 196–202.
- [71] R. Kimble, K.M. Keane, J.K. Lodge, G. Howatson, Methodological considerations for a vascular function test battery, *Int. J. Sports Med.* 40 (9) (2019) 601–608.
- [72] J. Yang, K.S. Carroll, D.C. Liebler, The expanding landscape of the thiol redox proteome, *Mol. Cell. Proteomics* 15 (1) (2016) 1–11.
- [73] R.P. Mason, Using anti-5,5-dimethyl-1-pyrroline N-oxide (anti-DMPO) to detect protein radicals in time and space with immuno-spin trapping, *Free Rad. Biol. Med.* 36 (10) (2004) 1214–1223.
- [74] R.P. Mason, D. Ganini, Immuno-spin trapping of macromolecules free radicals in vitro and in vivo - one stop shopping for free radical detection, *Free Rad. Biol. Med.* 131 (2019) 318–331.
- [75] F.C. Villafuerte, N. Corante, Chronic mountain sickness: clinical aspects, etiology, management, and treatment, *High Alt. Med. Biol.* 17 (2) (2016) 61–69.